Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody

References

• Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer 2014; 111:1888-98; PMID: 25025958; http://dx.doi.org/10.1038/bjc.2014.388
   PubMed Web of Science ®Google Scholar
• Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther. 2011; 11:263-75; PMID: 21342044; http://dx.doi.org/10.1586/era.10.226
   PubMed Web of Science ®Google Scholar
• Lipton A, Goodman L, Leitzel K, Cook J, Sperinde J, Haddad M, Kostler WJ, Huang W, Weidler JM, Ali S, et al. HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2013; 141:43-53; PMID: 23959396; http://dx.doi.org/10.1007/s10549-013-2665-0
   PubMed Web of Science ®Google Scholar
• Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol 2014; 232:219-29; PMID: 24105684; http://dx.doi.org/10.1002/path.4269
   PubMed Web of Science ®Google Scholar
• Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 17:2781-8; PMID: 10561353; http://dx.doi.org/10.1200/JCO.1999.17.9.2781
   PubMed Web of Science ®Google Scholar
• Ebb D, Meyers P, Grier H, Bernstein M, Gorlick R, Lipshultz SE, Krailo M, Devidas M, Barkauskas DA, Siegal GP et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group. J Clin Oncol 2012; 30:2545-51; PMID: 22665540; http://dx.doi.org/10.1200/JCO.2011.37.4546
   PubMed Web of Science ®Google Scholar
• Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res 2015; 21:526-33; PMID: 25424855; http://dx.doi.org/10.1158/1078-0432.CCR-14-1432
   Google Scholar
• Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 2014; 343:72-6; PMID: 24310612; http://dx.doi.org/10.1126/science.1241328
   Web of Science ®Google Scholar
• Mullard A. FDA approves first bispecific. Nature Reviews Drug Discovery 2015; 14:7; http://dx.doi.org/10.1038/nrd4531
   Web of Science ®Google Scholar
• Kershaw MH, Westwood JA, Slaney CY, Darcy PK. Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology 2014; 3:e16; PMID: 25505964; http://dx.doi.org/10.1038/cti.2014.7
   PubMedGoogle Scholar
• Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, et al. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007; 30:798-807; PMID: 18049331; http://dx.doi.org/10.1097/CJI.0b013e318156750c
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Schwab JH, Ferrone S, Ferrone CR. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. Clin Transpl 2013:453-63; PMID: 25095541
   PubMedGoogle Scholar
• Sanford M. Blinatumomab: first global approval. Drugs 2015; 75:321-7; PMID: 25637301; http://dx.doi.org/10.1007/s40265-015-0356-3
   PubMed Web of Science ®Google Scholar
• Shalaby MR, Shepard HM, Presta L, Rodrigues ML, Beverley PC, Feldmann M, Carter P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J Exp Med 1992; 175:217-25; PMID: 1346155; http://dx.doi.org/10.1084/jem.175.1.217
   PubMed Web of Science ®Google Scholar
• Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clinical pharmacology : advances and applications 2013; 5:5-11; PMID: 23671399; http://dx.doi.org/10.2147/CPAA.S42689
   PubMedGoogle Scholar
• Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, Wang BE, Li Y, Mathieu M, Li G et al. Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells. Cancer Res 2014; 74:5561-71; PMID: 25228655; http://dx.doi.org/10.1158/0008-5472.CAN-13-3622-T
   PubMed Web of Science ®Google Scholar
• Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012; 503:255-68; PMID: 22230572; http://dx.doi.org/10.1016/B978-0-12-396962-0.00010-0
   PubMed Web of Science ®Google Scholar
• Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 2014; 13:1803-12; PMID: 24944121; http://dx.doi.org/10.1158/1535-7163.MCT-13-0933
   PubMed Web of Science ®Google Scholar
• Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, Wittrup KD. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221-8; PMID: 20019028; http://dx.doi.org/10.1093/protein/gzp077
   PubMed Web of Science ®Google Scholar
• Xu H, Cheng M, Guo H, Chen Y, Huse M, Cheung NK. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 2015; 3:266-77; PMID: 25542634; http://dx.doi.org/10.1158/2326-6066.CIR-14-0230-T
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515:568-71; PMID: 25428505; http://dx.doi.org/10.1038/nature13954
   PubMed Web of Science ®Google Scholar
• Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W et al. Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Cancer Cell 2016; 29:285-96; PMID: 26977880; http://dx.doi.org/10.1016/j.ccell.2016.02.004
   PubMed Web of Science ®Google Scholar
• Gajewski TF. The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Semin Oncol 2015; 42:663-71; PMID: 26320069; http://dx.doi.org/10.1053/j.seminoncol.2015.05.011
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 2014; 41:174-84; PMID: 24787291; http://dx.doi.org/10.1053/j.seminoncol.2014.02.003
   PubMed Web of Science ®Google Scholar
• Laoui D, Van Overmeire E, De Baetselier P, Van Ginderachter JA, Raes G. Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression. Frontiers in immunology 2014; 5:489; PMID: 25339957; http://dx.doi.org/10.3389/fimmu.2014.00489
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014; 27:1-7; PMID: 24413387; http://dx.doi.org/10.1016/j.coi.2013.12.005
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 2013; 34:137-43; PMID: 23103127; http://dx.doi.org/10.1016/j.it.2012.10.001
   PubMed Web of Science ®Google Scholar
• Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol 2014; 4:385; PMID: 25642417; http://dx.doi.org/10.3389/fonc.2014.00385
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. J Clin Oncol 2015; 33:1974-82; PMID: 25605845; http://dx.doi.org/10.1200/JCO.2014.59.4358
   Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID: 21436444; http://dx.doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Farolfi A, Ridolfi L, Guidoboni M, Nicoletti SV, Piciucchi S, Valmorri L, Costantini M, Scarpi E, Amadori D, Ridolfi R. Ipilimumab in advanced melanoma: reports of long-lasting responses. Melanoma research 2012; 22:263-70; PMID: 22516968; http://dx.doi.org/10.1097/CMR.0b013e328353e65c
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371:2189-99; PMID: 25409260; http://dx.doi.org/10.1056/NEJMoa1406498
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280):1463-9; PMID: 26940869; http://dx.doi.org/10.1126/science.aaf1490
   PubMed Web of Science ®Google Scholar
• Seliger B, Kiessling R. The two sides of HER2/neu: immune escape versus surveillance. Trends Mol Med 2013; 19:677-84; PMID: 24035606; http://dx.doi.org/10.1016/j.molmed.2013.08.003
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheng M, Cheung IY, Cheung NK. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. OncoImmunology 2015; 4:e989776; PMID: 26137406; http://dx.doi.org/10.4161/2162402X.2014.989776
   PubMed Web of Science ®Google Scholar
• Lum LG, Thakur A. Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2011; 25:365-79; PMID: 22050339; http://dx.doi.org/10.2165/11595950-000000000-00000
   PubMed Web of Science ®Google Scholar
• Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 2012; 59:1198-205; PMID:22707078; http://dx.doi.org/10.1002/pbc.24237
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Dual targeting strategies with bispecific antibodies. MAbs 2012; 4:182-97; PMID: 22453100; http://dx.doi.org/10.4161/mabs.4.2.19000
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843-51; PMID: 20179677; http://dx.doi.org/10.1038/mt.2010.24
   PubMed Web of Science ®Google Scholar
• Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 2002; 8:788-93; PMID: 11895910
   PubMed Web of Science ®Google Scholar
• Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS, Dishop MK, Kleinerman EE, Pule M, Rooney CM et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009; 17:1779-87; PMID: 19532139; http://dx.doi.org/10.1038/mt.2009.133
   PubMed Web of Science ®Google Scholar
• Rainusso N, Brawley VS, Ghazi A, Hicks MJ, Gottschalk S, Rosen JM, Ahmed N. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 2012; 19:212-7; PMID: 22173710; http://dx.doi.org/10.1038/cgt.2011.83
   PubMed Web of Science ®Google Scholar
• Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21:581-90; PMID: 25939063; http://dx.doi.org/10.1038/nm.3838
   PubMed Web of Science ®Google Scholar
• Chen C-T, Kim H, Liska D, Gao S, Christensen J, Weiser M. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells. Mol Cancer Ther 2012; 11:660-9; PMID: 22238368; http://dx.doi.org/10.1158/1535-7163.MCT-11-0754
   PubMed Web of Science ®Google Scholar
• Koo GC, Hasan A, O'Reilly RJ. Use of humanized severe combined immunodeficient mice for human vaccine development. Expert Rev Vaccines 2009; 8:113-20; PMID: 19093778; http://dx.doi.org/10.1586/14760584.8.1.113
   PubMed Web of Science ®Google Scholar
• Andrade D, Redecha PB, Vukelic M, Qing X, Perino G, Salmon JE, Koo GC. Engraftment of peripheral blood mononuclear cells from systemic lupus erythematosus and antiphospholipid syndrome patient donors into BALB-RAG-2−/− IL-2Rgamma−/− mice: a promising model for studying human disease. Arthritis Rheum 2011; 63:2764-73; PMID: 21560114; http://dx.doi.org/10.1002/art.30424
   PubMed Web of Science ®Google Scholar